Using “building block” protein technologies, we can make and test next-generation cancer treatments at scale.
Using this modular approach, we create and find new drugs that can't otherwise be identified.
Backed By:
Rapid drug design using building blocks. Our modular LiliumX™ Universal Assembly Platform™ can rapidly and iteratively build libraries of drug candidates from existing components, such as fragments of approved antibodies and small molecules.
Due to our “building block” design, we can bring together multiple pieces at once to generate more powerful drug candidates across multiple fields of next-generation antibody engineering, creating unique synergies.
We focus on treating solid tumours with bispecific antibody-drug conjugates. Aiming at two cellular markers at once to differentiate malignant from healthy tissue – this enables us to deliver drugs more specifically and more effectively.
Noteworthy
Noteworthy
Contact Us
Imperial Translation & Innovation Hub
84 Wood Lane
London
W12 0BZ
England
Imperial Translation & Innovation Hub
84 Wood Lane
London
W12 0BZ
England